Who founded iTeos Therapeutics?

iTeos Therapeutics was founded by Michel Detheux in 2019.

Who are iTeos Therapeutics's investors?

iTeos Therapeutics's investors include VIVES Partners, MPM BioImpact.

iTeos Therapeutics has disclosed $125.4M raised across 1 round.

iTeos Therapeutics is headquartered in Cambridge, US.

Cambridge, US · Founded 2019 · Delaware corporation · 2 known investors

Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.

iTeos Therapeutics was founded in 2019 by Michel Detheux.

Michel DetheuxFounder

David HallalNamed on SEC filing

Priyanka BelawatNamed on SEC filing

CHris BuyseNamed on SEC filing

Jonathan SkipperNamed on SEC filing

Detlev Biniszkiewicz inBoard of Directors2019–2023Managing Director at MPM BioImpact

Ansbert Gadicke inBoard directorChairman at MPM BioImpact

Tim Van HauwermeirenBoard director

Form D private placements

$125.4M disclosed across 1 round · 2020

▶$125.4MraisedApr 2020 · 36 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

2 people who came through iTeos Therapeutics went on to found or lead other companies.

What does iTeos Therapeutics do?: Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.
Who founded iTeos Therapeutics?: iTeos Therapeutics was founded by Michel Detheux in 2019.
Who are iTeos Therapeutics's investors?: iTeos Therapeutics's investors include VIVES Partners, MPM BioImpact.
How much funding has iTeos Therapeutics raised?: iTeos Therapeutics has disclosed $125.4M raised across 1 round.
Where is iTeos Therapeutics headquartered?: iTeos Therapeutics is headquartered in Cambridge, US.